The dosage may be increased to 9 mg, 14.5 mg, or 17.2 mg after at least 30 days at each level based on treatment response and tolerability, according to the FDA
It can also affect immunosuppressants such as cyclosporine and some antipsychotics
Vit-D deficiency is a risk factor for unregulated cytokine storm and hyper-inflammation in COVID-19 patients 697
Persistent tiredness can signal undereating relative to your activity level, inadequate micronutrient intake (especially iron, B12, and magnesium), or an underlying condition unrelated to semaglutide
Not for human consumption or therapeutic applications
What can we conclude To date, we have not seen robust reports that persons with obesity or overweight taking GLP-1 medications experience greater SMM loss than persons with obesity or overweight taking non-GLP-1 medications (after controlling for greater total weight loss)